{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:03:25Z","timestamp":1789560205954,"version":"build-2803163510"},"reference-count":54,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Assessing fatalities linked to new psychoactive substances (NPS) often remains challenging. This study investigates a fatal intoxication involving the novel phencyclidine derivative 3\u2010chloro\u2010phencyclidine (3\u2010Cl\u2010PCP), analyzing its phase I metabolism aided by pooled human liver microsomes (pHLMs) and supported by in silico models. Postmortem samples (bile, urine, cardiac and femoral blood, and gastric contents) and three syringes were collected from a fatal intoxication case. Quantification was performed using liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS). In\u00a0vitro metabolism studies employed pHLM incubation, with metabolites tentatively identified by liquid chromatography\u2010quadrupole time\u2010of\u2010flight mass spectrometry (LC\u2010QTOF\u2010MS). To evaluate phase II metabolism, urine and bile samples were measured with and without \u03b2\u2010glucuronidase treatment. 3\u2010Cl\u2010PCP concentrations ranged from 610\u2009ng\/mL in cardiac blood to 830\u2009ng\/mL in femoral blood. Higher levels were detected in urine (1200\u2009ng\/mL) and bile (4300\u2009ng\/mL). Seven phase I metabolites were tentatively identified in\u00a0vitro and postmortem, primarily involving hydroxylation of the cyclohexyl (M1\u2013M3) and piperidine (M4\u2013M5) rings. Additionally, piperidine ring\u2010opened carboxyl (M6) and ring\u2010opened alcohol (M7) metabolites were tentatively identified. Post\u2010enzyme urine analysis revealed extensive glucuronidation of metabolites M1\u2013M5, with M4 (hydroxyl piperidine) showing the highest abundance. Bile showed elevated abundance of unconjugated metabolites, particularly M6. Metabolites M4\u2013M7 were detected in all investigated matrices. Unchanged 3\u2010Cl\u2010PCP predominantly accumulated in bile. Urine analysis should prioritize the parent compound along with the metabolites hydroxy cyclohexyl (M3), hydroxy piperidine (M4), and piperidine ring\u2010opened carboxyl (M6) and should include a prior \u03b2\u2010glucuronidase cleavage step.<\/jats:p>","DOI":"10.1002\/dta.70097","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:43:47Z","timestamp":1779669827000},"page":"1036-1053","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I Metabolism of Novel Phencyclidine Derivative 3\u2010Cl\u2010PCP:\n                    <i>In Vitro<\/i>\n                    Studies With Pooled Human Liver Microsomes and Investigation of a Post\u2010Mortem Case"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8693-9312","authenticated-orcid":false,"given":"Johannes","family":"Kutzler","sequence":"first","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology Medical Center \u2013 University of Freiburg  Freiburg im Breisgau Germany"},{"name":"Medical Faculty University of Freiburg  Freiburg im Breisgau Germany"},{"name":"Hermann Staudinger Graduate School University of Freiburg  Freiburg im Breisgau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8678-8480","authenticated-orcid":false,"given":"Tobias","family":"Veit","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology Medical Center \u2013 University of Freiburg  Freiburg im Breisgau Germany"},{"name":"Medical Faculty University of Freiburg  Freiburg im Breisgau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Keller","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology University of Salzburg  Salzburg Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1883-2804","authenticated-orcid":false,"given":"Volker","family":"Auw\u00e4rter","sequence":"additional","affiliation":[{"name":"Institute of Forensic Medicine, Forensic Toxicology Medical Center \u2013 University of Freiburg  Freiburg im Breisgau Germany"},{"name":"Medical Faculty University of Freiburg  Freiburg im Breisgau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"European Drug Report","author":"European Union Drugs Agency","year":"2025"},{"key":"e_1_2_8_3_1","unstructured":"United Nations Office on Drugs and Crime \u201cWorld Drug Report 2025 \u201d United Nations Vienna United Nations Publication (2025). [Online]. Available:https:\/\/www.unodc.org\/unodc\/en\/data\u2010and\u2010analysis\/world\u2010drug\u2010report\u20102025.html."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1620"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-20790-2_124-2"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2014.924962"},{"key":"e_1_2_8_7_1","volume-title":"Methoxetamine: Report on the Risk Assessment of 2\u2010(3\u2010Methoxyphenyl)\u20102\u2010(Ethylamino) Cyclohexanone (Methoxetamine) in the Framework of the Council Decision on New Psychoactive Substances","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2014"},{"key":"e_1_2_8_8_1","unstructured":"EMCDDA \u201cFormal Notification of 1\u2010[1\u2010(3\u2010Chlorophenyl)Cyclohexyl]Piperidine (3\u2010Cl\u2010PCP) by Slovenia as a New Psychoactive Substance Under the Terms of Regulation (EU) 2017\/2101 \u201d EMCDDA Lisbon Action on New Drugs Sector EMCDDA EU\u2010EWS\u2010RCS\u2010FN\u20102021\u20100004 Jan. (2021)."},{"key":"e_1_2_8_9_1","unstructured":"EUDA \u201cFormal Notification of 2\u2010(Methylamino)\u20102\u2010(Thiophen\u20102\u2010Yl)Cyclohexan\u20101\u2010One (Tilmetamine) by Finland as a New Psychoactive Substance Under the Terms of Regulation (EU) No 2023\/1322 and Council Framework Decision 2004\/757\/JHA \u201d EUDA Lisbon Early Warning Alert Laboratory Network Sector EUDA EU\u2010EWS\u2010RCS\u2010FN\u20102025\u20100041 Nov. (2025)."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1861"},{"key":"e_1_2_8_11_1","unstructured":"EMCDDA \u201cFormal Notification of 2\u2010(Ethylamino)\u20102\u2010(3\u2010Fluorophenyl)Cyclohexan\u20101\u2010One (Fluorexetamine) by Belgium as a New Psychoactive Substance Under the Terms of Regulation (EC) No 1920\/2006 and Council Framework Decision 2004\/757\/JHA \u201d EMCDDA Lisbon Action on New Drugs Sector EMCDDA EU\u2010EWS\u2010RCS\u2010FN\u20102022\u20100040 Dec. (2022)."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.177674"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2022.111501"},{"key":"e_1_2_8_14_1","unstructured":"EUDA \u201cFormal Notification of N\u2010(1 2\u2010Diphenylethyl)Propan\u20101\u2010Amine (N\u2010Propyl Ephenidine) by Portugal as a New Psychoactive Substance Under the Terms of Regulation (EU) No 2023\/1322 and Council Framework Decision 2004\/757\/JHA \u201d EUDA Lisbon Early Warning Alert Laboratory Network Sector EUDA EU\u2010EWS\u2010RCS\u2010FN\u20102025\u20100043 Dec. (2025)."},{"key":"e_1_2_8_15_1","unstructured":"EMCDDA \u201cFormal Notification of 2\u2010(Ethylamino)\u20102\u2010(3\u2010Hydroxyphenyl)\u2010Cyclohexanone (Hydroxetamine) by Slovenia as a New Psychoactive Substance Under the Terms of Regulation (EC) No 1920\/2006 and Council Framework Decision 2004\/757\/JHA \u201d EMCDDA Lisbon Action on New Drugs Sector EMCDDA EU\u2010EWS\u2010RCS\u2010FN\u20102021\u20100029 Aug. (2021)."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.170473"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054628"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2017.00152"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415574"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010018\u20101558\u20109"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3657"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.117276"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010025\u201004010\u20106"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010025\u201004097\u2010x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3668"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2025.112364"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X14666161018151716"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/20961790.2021.1928821"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2807"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3538"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.0c00224"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2042\u20105783\u20102\u20101"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkac057"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010025\u201000746\u2010z"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204\u2010025\u201004023\u20101"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300030"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010018\u20100447\u20104"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/bkae013"},{"issue":"1","key":"e_1_2_8_39_1","first-page":"1","article-title":"Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch\u2010toxikologischen Untersuchungen","volume":"85","author":"Paul L.","year":"2018","journal-title":"Toxichem Krimtech"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13321\u2010025\u201001097\u2010y"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002667"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009\u20102797(03)00020\u20106"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920011795101822"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2017.1384967"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.112782"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2018.1555587"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-813602-7.00003-X"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/01483918108064815"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378\u20104347(96)00472\u20100"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010008\u20101962\u20107"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5482"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27030907"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trac.2023.117045"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202000060"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010021\u201000585\u20108"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.70097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:10:20Z","timestamp":1785777020000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.70097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/dta.70097"],"URL":"https:\/\/doi.org\/10.1002\/dta.70097","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"2026-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}